ReviewCurrent diabetes reports2011
Cell-based therapies for diabetic retinopathy.
Review in Current diabetes reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial.Diabetologia · 2021Trial
- Aldose Reductase as a Key Target in the Prevention and Treatment of Diabetic Retinopathy: A Comprehensive Review.Biomedicines · 2024Review
- Update of application of olfactory ensheathing cells and stem cells/exosomes in the treatment of retinal disorders.Stem cell research & therapy · 2022Review
- Novel Cell-Based and Tissue Engineering Approaches for Induction of Angiogenesis as an Alternative Therapy for Diabetic Retinopathy.International journal of molecular sciences · 2020Review
- Impaired Regeneration Potential in Urinary Stem Cells Diagnosed from the Patients with Diabetic Nephropathy.Theranostics · 2019Article
- Bone Marrow CD133Cell transplantation · 2018Article
- Role of pericytes in the retina.Eye (London, England) · 2018Article
- Vascular stem/progenitor cells: functions and signaling pathways.Cellular and molecular life sciences : CMLS · 2018Review
- Diabetic corneal neuropathy: clinical perspectives.Clinical ophthalmology (Auckland, N.Z.) · 2018Review
- Diabetic retinopathy: current understanding, mechanisms, and treatment strategies.JCI insight · 2017Review
- Concise Review: Functional Definition of Endothelial Progenitor Cells: A Molecular Perspective.Stem cells translational medicine · 2016Review
- Neurovascular cross talk in diabetic retinopathy: Pathophysiological roles and therapeutic implications.American journal of physiology. Heart and circulatory physiology · 2016Review
- Perivascular Progenitor Cells Derived From Human Embryonic Stem Cells Exhibit Functional Characteristics of Pericytes and Improve the Retinal Vasculature in a Rodent Model of Diabetic Retinopathy.Stem cells translational medicine · 2016Article
- Role of Acid Sphingomyelinase in Shifting the Balance Between Proinflammatory and Reparative Bone Marrow Cells in Diabetic Retinopathy.Stem cells (Dayton, Ohio) · 2016Article
- Stem cell therapies in the treatment of diabetic retinopathy and keratopathy.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- Promoting vascular repair in the retina: can stem/progenitor cells help?Eye and brain · 2016Review
- Enhanced endoplasmic reticulum stress in bone marrow angiogenic progenitor cells in a mouse model of long-term experimental type 2 diabetes.Diabetologia · 2015Article
- Effects of diabetes on the eye.Investigative ophthalmology & visual science · 2013Review
- Circulating mononuclear progenitor cells: differential roles for subpopulations in repair of retinal vascular injury.Investigative ophthalmology & visual science · 2013Article
- Shaping the eye from embryonic stem cells: Biological and medical implications.World journal of stem cells · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Autologous endothelial progenitor cell (EPC) populations represent a novel treatment for therapeutic revascularization and vascular repair for diabetic patients with complications including diabetic retinopathy. Current therapies are applicable to late-stage disease and carry significant side effects, whereas cell-based therapy may provide an alternative by repairing areas of vasodegeneration and reversing ischemia. However, EPCs from diabetic patients with vascular complications are dysfunctional. Moreover, the diabetic environment poses its own challenges and complicates the use of autologous EPCs. Before EPCs become the ideal "cell therapy," the optimal EPC must be determined, any functional dysfunction must be corrected prior to use, and the diabetic milieu will require modification to accept the EPCs. This review describes the rationale for harnessing the vascular reparative properties of EPCs with emphasis on the molecular and phenotypic nature of healthy EPCs, how diabetes alters them, and novel strategies to improve dysfunctional EPCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.